MK-7762 / Merck (MSD), Bill & Melinda Gates Foundation - LARVOL DELTA

Bactericidal Activity of TBD09 in Combination With Other Drugs in Pulmonary Tuberculosis (clinicaltrials.gov) - P2 | N=150 | Recruiting | Sponsor: Gates Medical Research Institute | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Bactericidal Activity of TBD09 in Combination With Other Drugs in Pulmonary Tuberculosis (clinicaltrials.gov) - P2 | N=150 | Not yet recruiting | Sponsor: Gates Medical Research Institute

New P2 trial • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Current Status and Perspectives of Antibacterial Agents Belonging to 2-Oxazolidinones. (PubMed, Pharmaceuticals (Basel)) - "Tedizolid phosphate was the second commercially available oxazolidinone antibiotic approved, followed by other oxazolidinones (contezolid, radezolid, ranbezolid, sutezolid, delpazolid, cadazolid, TBI-233 and MK-7762) that are in clinical study. Three literature databases, i.e., PubMed/MEDLINE, Google Scholar and Scopus, were used for the literature search, particularly focusing on the last five years, and screened using different keywords. The design of new drugs belonging to this class may be of considerable interest to researchers and clinicians, contributing to the discovery of new antibiotics that retain antibacterial activity but have fewer side effects."

Journal • Review • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBD09 (clinicaltrials.gov) - P1 | N=36 | Completed | Sponsor: Gates Medical Research Institute | Active, not recruiting ➔ Completed

Trial completion

Discovery and development of a new oxazolidinone with reduced toxicity for the treatment of tuberculosis. (PubMed, Nat Med) - "Four-month safety studies in both rats (N = 20) and dogs (N = 24) showed no changes in hematology parameters at exposures well above the 100-mg predicted human dose. These data will enable MK-7762 to be explored as a component of new tuberculosis treatment combinations for all forms of the disease."

Journal • Hematological Disorders • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBD09 (clinicaltrials.gov) - P1 | N=36 | Active, not recruiting | Sponsor: Gates Medical Research Institute | Recruiting ➔ Active, not recruiting

Enrollment closed

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBD09 (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Gates Medical Research Institute | Not yet recruiting ➔ Recruiting

Enrollment open

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBD09 (clinicaltrials.gov) - P1 | N=36 | Not yet recruiting | Sponsor: Gates Medical Research Institute

New P1 trial

Safety, Tolerability, Pharmacokinetics (PK), and Food Effect of MK-7762 in Healthy Adults (clinicaltrials.gov) - P1 | N=119 | Completed | Sponsor: Bill & Melinda Gates Medical Research Institute | Recruiting ➔ Completed | Trial completion date: Oct 2024 ➔ Mar 2024 | Trial primary completion date: Oct 2024 ➔ Mar 2024

Trial completion • Trial completion date • Trial primary completion date • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Safety, Tolerability, Pharmacokinetics (PK), and Food Effect of MK-7762 in Healthy Adults (clinicaltrials.gov) - P1 | N=96 | Recruiting | Sponsor: Bill & Melinda Gates Medical Research Institute | Trial completion date: Apr 2024 ➔ Oct 2024

Trial completion date • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Safety, Tolerability, Pharmacokinetics (PK), and Food Effect of MK-7762 in Healthy Adults (clinicaltrials.gov) - P1 | N=96 | Recruiting | Sponsor: Bill & Melinda Gates Medical Research Institute

New P1 trial • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis